Stockscreener 앱 받기
27.20
2.65%
-0.74
시간 외 거래:
27.20
전일 마감가:
$27.94
열려 있는:
$27.51
하루 거래량:
2.36M
Relative Volume:
1.39
시가총액:
$4.48B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
13.95
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
-5.59%
1개월 성능:
-20.07%
6개월 성능:
-3.17%
1년 성능:
+14.43%
1일 변동 폭
$26.77
$27.68
1주일 범위
$25.56
$28.09
52주 변동 폭
$22.90
$36.45
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
ALKS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
27.20 | 4.48B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
146.76 | 65.46B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.65 | 46.11B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 45.85B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.43 | 15.39B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
285.19 | 12.81B | 2.76B | 1.11B | 898.10M | 22.77 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alkermes (ALKS) Announces CFO Transition Following Iain M. Brown's Passing - GuruFocus
Alkermes' CFO Iain Brown passes away (ALKS:NASDAQ) - Seeking Alpha
Alkermes CFO Iain M. Brown passes away By Investing.com - Investing.com India
AlkermesCFO Iain M. Brown Passes AwaySEC Filing - MarketScreener
Alkermes (ALKS) announces passing of Chief Financial Officer - StreetInsider
Alkermes plc Announces Demise of Iain M. Brown, Chief Financial Officer - MarketScreener
Mural Oncology cuts 90% of staff, pulls plug on cancer drug - The Business Journals
5 Top Psychedelic Stocks (2025) for Mental Health Investing - Securities.io
Alkermes to Participate in Two Upcoming Investor Conferences - Seeking Alpha
Alkermes To Present At Needham Virtual Healthcare Conference; Webcast At 11:45 AM ET - Nasdaq
Opioid Use Disorder Market Generated Opportunities, Future - openPR.com
Alcohol Addiction Treatments Market Detailed in New Research - openPR.com
Opioid Withdrawal Treatment Market Emerging Trends and Growth - openPR.com
Relative Strength Alert For Alkermes - Nasdaq
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 - MSN
RBC Trims Price Target on Alkermes to $39 From $40, Keeps Sector Perform Rating - MarketScreener
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Malaysian Reserve
Alkermes Begins Idiopathic Hypersomnia Study On ALKS 2680 - Barchart.com
Nanotechnology Drug Delivery Market Exclusive Trends Analysis - openPR.com
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - Sharecast News
Alkermes Announces Initiation Of Vibrance-3 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Idiopathic Hypersomnia - MarketScreener
(ALKS) Trading Report - news.stocktradersdaily.com
Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating - MarketScreener
What 5 Analyst Ratings Have To Say About Alkermes - Benzinga
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PR Newswire
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? - MSN
Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha
Liposomal Drug Delivery Market Detailed In New Research Report - openPR.com
First Week of November 21st Options Trading For Alkermes (ALKS) - Nasdaq
Controlled Release Drug Delivery Market to Witness Massive - openPR.com
Alkermes price target raised to $35 from $34 at BofA - MSN
Where are the Opportunities in (ALKS) - news.stocktradersdaily.com
Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? - Yahoo Finance
Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Alkermes PLC Reports Q4 Revenue of $430 Million, Beating Estimat - GuruFocus.com
Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years - Yahoo Finance
Alkermes (NASDAQ:ALKS) shareholders have earned a 19% CAGR over the last five years - Simply Wall St
Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says - Marketscreener.com
RBC Capital Initiates Coverage of Alkermes (ALKS) with Sector Perform Recommendation - Nasdaq
S&P 500 Futures Drop in Premarket Trading; Alkermes, Intel Lead - Barron's
Alkermes initiated with a Sector Perform at RBC Capital - TipRanks
Charles Schwab Investment Management Inc. Sells 38,088 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights - Investing.com India
Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com South Africa
Alkermes to Participate in Upcoming Investor Conferences - GuruFocus.com
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times
Mural Oncology Slashes Losses by 42% as Two Major Cancer Trial Results Approach - Stock Titan
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.70%
4.10%
자본화:
|
볼륨(24시간):